Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director
Julian brings deep expertise in the development and commercialising of repurposed and reprofiled compounds. He was co-founder and CEO of Acacia Pharma Group plc, a hospital pharmaceuticals company which launched its lead product BARHEMSYS®, a repurposed amisulpiride formulation for the management of post-operative nausea and vomiting, in 2020. During his time at Acacia, Julian helped raise approximately £100 million in private and public funding and led its flotation on Euronext in 2018. Prior to this, Julian was co-founder and Commercial Director of Arakis Limited, a specialist pharmaceutical repurposing company that was sold to Sosei in 2005 for £107 million, having licensed Seebri®/Ultibro® to Novartis. In his more than 30 years of commercial and technical experience in the pharmaceutical industry, Julian has also worked at Chiroscience Plc, Mundipharma International Limited, BTG and GSK. He is Non-Executive Director of Exvastat and Nuformix plc and holds a degree in pharmacy and a PhD in pharmaceutics from the University of Nottingham.
For further information, contact:
Jenny Barnett, CEO
Richard Hayhurst/Janet Joy
E: Richard@rhapr.eu or firstname.lastname@example.org
Tel: +44 7711 821527
Notes to Editors:
About Monument Therapeutics
Monument Therapeutics is bringing stratified medicine to neuroscience drug development. The company uses proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, which are then matched with appropriately targeted compounds.
For further information visit www.monumenttx.com